[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-adult-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-adult-onset":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644625","phase-2-a-randomized-double-blind-placebo-controlled-study-evaluating-the-effect-of-lae102-injection-in-combination-with-tirzepatide-on-body-in-obese-participants-100644625",false,"NCT07671391","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the Informed Consent Form (ICF);\n2. Male or female participants aged between 18 and 75 years (inclusive) at the time of signing the ICF;\n3. BMI ranging from 28.0 to 40.0 kg\u002Fm2 during the screening;\n4. Self-reporting at least one experience of weight loss failure after adjusting diet and exercise, and within the previous 3 months, the weight change after only dietary and exercise adjustments was less than 5%;\n\nExclusion Criteria:\n\n1. A clear diagnosis of type 1, type 2 diabetes or other types of diabetes (excluding gestational diabetes);\n2. Screening criteria: Glycated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL.\n\n   Obesity related:\n3. Diagnosed with secondary obesity;\n4. Previously underwent surgical or endoscopic weight loss metabolic surgery (except for local liposuction within 1 year before screening) or gastric balloon implantation, or planned to undergo any weight loss surgery or receive other weight loss treatments during the study;\n5. Uncontrolled thyroid disease, or screening criteria.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.",[27],"Obesity Adult Onset",[29,27,30],"LAE102 injection","Investigator-initiated trial","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":21},"2026-08",{"date":39,"type":21},"2027-12",{"name":41,"class":42},"Shanghai Zhongshan Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100507429","phase-2-a-randomised-controlled-trial-of-a-low-energy-diet-for-improving-functional-status-in-heart-failure-with-preserved-ejection-fraction-preserved-ejection-fraction-100507429","NCT05887271","A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction","A Multi-Ethnic, Multi-centre raNdomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction (AMEND-preserved)","AMEND","Inclusion Criteria:\n\n1. Established clinical diagnosis of heart failure with preserved ejection fraction HFpEF (EF\\>45%) made by a cardiologist or a primary care physician with heart failure expertise, or a heart failure nurse\n2. Clinically stable for ≥ 3 months (no admissions to hospital)\n3. Obesity (BMI ≥30kg\u002Fm2 if white European or ≥27kg\u002Fm2 if Asian, Middle Eastern or Black ethnicity)\n4. Age ≥18\n\nExclusion Criteria:\n\n1. Inability to walk\u002Fundertake 6-minute walk test\n2. Inability to follow a low-energy MRP\n3. HFpEF due to infiltrative cardiomyopathy (cardiac amyloidosis or sarcoidosis), genetic hypertrophic cardiomyopathy, restrictive cardiomyopathy\u002Fpericardial disease or congenital heart disease.\n4. Recovered EF (previous EF \\\u003C 40%) unless reduced EF was in context of tachycardia induced cardiomyopathy (eg AF\u002FAflutter).\n5. Known heritable, idiopathic or drug-induced pulmonary arterial hypertension\n6. Severe chronic obstructive pulmonary disease (FEV1\\\u003C 1.0L)\n7. Severe primary valvular heart disease\n8. Anaemia (Hb\\\u003C100g\u002FL)\n9. Severe renal disease (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n10. Weight loss \\> 5kg in preceding 3 months.\n11. Symptomatic gallstones (including biliary colic) or cholecystitis within last 3 months\n12. Active substance abuse (drugs or alcohol)\n13. History of bariatric surgery in the last 3 years\n14. Active illness likely to cause change in weight\n15. Women who are pregnant or are considering pregnancy\n16. People currently participating in another clinical research trial that is likely to affect diet or weight change.\n17. History of a severe mental illness including an eating disorder\n\n17\\. Individuals with a diagnosis of Type 1 diabetes mellitus.",{"count":52,"type":21},63,[24,54],"PHASE3","Heart failure with preserved ejection fraction (HFpEF) is a common and serious complication of obesity and type 2 diabetes (T2D). HFpEF occurs when the heart muscle unable to relax efficiently to pump the blood around the body. This leads to fluid build-up, breathlessness and inability to tolerate physical exertion. People who develop HFpEF do less well because treatment options are limited. Pilot data in patients with obesity and diabetes and a small number of patients with HFpEF have shown improvements in exercise capacity and reversal of changes in the heart and blood vessels. This study will assess if this is achievable in a multi-ethnic cohort of patients with established HFpEF. A total of 63 adults will be invited and allocate by chance into two groups: 1) 12-weeks of a low calorie diet or 2) Standard care and health advice on how to lose weight followed by the option to have the low calorie diet after 12-weeks. The study will determine if weight loss over 12 weeks can improve heart function, symptoms and ability to exercise. Additionally, participants' views on changing their diet and how this has impacted their symptoms will be sought during the study in an optional interview. This will help guide treatments planning in the future to get maximum benefits, and to individualize support to patients from different cultural backgrounds.",[57,58,59,60,27],"Heart Failure With Preserved Ejection Fraction","Heart Failure, Diastolic","Diabetes Mellitus, Type 2","Diabetes Mellitus Type 2 in Obese",[62,63,64,65,66,67,68,69],"Heart failure with preserved ejection fraction","Diastolic heart failure","Type 2 diabetes mellitus","Obesity","Meal replacement plan","Cardiac magnetic resonance imaging","Exercise intolerance","Diabetes remission","RECRUITING",{"date":72,"type":35},"2026-06-25",{"date":74,"type":35},"2023-12-05",{"date":76,"type":21},"2026-06-30",{"name":78,"class":42},"University of Leicester",3]